Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
27.8% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
0
users have commented on this narrative
11
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
25.2% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
5.0% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Truist Financial
AN
AnalystConsensusTarget
Consensus Narrative from 21 Analysts
Digital Adoption And Sunbelt Expansion Will Advance Market Position
Key Takeaways Digital adoption and technology investments are reducing operational costs, improving efficiency, and positioning Truist for ongoing revenue and margin expansion. Success in attracting younger, higher-income clients and strengthening in the Sunbelt region is boosting non-interest income, driving diversified growth in wealth and commercial banking services.
View narrative
US$48.69
FV
12.0% undervalued
intrinsic discount
7.47%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
41
users have followed this narrative
4 days ago
author updated this narrative
Under Armour
AN
AnalystConsensusTarget
Consensus Narrative from 20 Analysts
New Premium Footwear And Apparel Will Shape Future Success
Key Takeaways Under Armour's focus on reducing discounts and revamping product lines aims to boost pricing power and enhance revenue quality. Strategic shifts like a category-managed model and streamlined SKUs may improve operational efficiency and long-term profitability.
View narrative
US$6.90
FV
25.7% undervalued
intrinsic discount
2.31%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
22
users have followed this narrative
Updated
narrative
Addex Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
CNS And Respiratory Therapies Will Unlock Expanding Global Markets
Key Takeaways Differentiated CNS and respiratory pipeline, positive clinical progress, and strategic partnerships position Addex for long-term growth with stabilized earnings and mitigated R&D risk. Expanded intellectual property and global market trends enhance future out-licensing opportunities and scalability potential for Addex's novel therapies.
View narrative
CHF 0.16
FV
64.4% undervalued
intrinsic discount
108.83%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Polarean Imaging
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Pharma Trials And Pediatric FDA Approval Will Open Global Markets
Key Takeaways New revenue vertical in pharma-sponsored trials and FDA approval for younger patients expand market opportunities and potential revenue streams. Successful reimbursement pathway and international expansion indicate future growth and reduced financial risk.
View narrative
UK£0.079
FV
87.4% undervalued
intrinsic discount
77.87%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
4 days ago
author updated this narrative
Marley Spoon Group
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Integrated Platform And Asset-Light Model Will Improve Efficiency
Key Takeaways Transition to an integrated platform model and refined marketing boost customer lifetime value and improve revenue growth and net margins. Cost reduction and asset-light model in U.S. enhance operational efficiency, potentially driving future earnings and improved EBITDA.
View narrative
€1.80
FV
77.8% undervalued
intrinsic discount
1.61%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
4 days ago
author updated this narrative
Co-Diagnostics
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Clinical Advancements And Cloud Integration Will Shape Molecular Diagnostics
Key Takeaways Expanding into high-prevalence markets with advanced diagnostic tests and digital health integration positions the company for substantial growth and competitive differentiation. Building local infrastructure and securing global health partnerships supports cost efficiency, recurring revenues, and long-term improvement in margins.
View narrative
US$5.50
FV
95.4% undervalued
intrinsic discount
186.13%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
4
users have followed this narrative
4 days ago
author updated this narrative
Tortilla Mexican Grill
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
Technology Investments And European Expansion Will Fuel Fast Casual Evolution
Key Takeaways Technology adoption, menu innovation, and cost management are enhancing efficiency, customer loyalty, and margins, supporting sustainable growth and operational resilience. Expansion into Europe and a growing franchise network are expected to accelerate top-line growth and drive higher-margin, asset-light revenue streams.
View narrative
UK£0.68
FV
34.5% undervalued
intrinsic discount
7.24%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
4
users have followed this narrative
4 days ago
author updated this narrative
BioAtla
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Mec-V And ROR2-ADC Programs Will Achieve Clinical Milestones
Key Takeaways Promising results in clinical programs and strategic partnerships indicate potential for increased revenue, improved net margins, and financial stability through collaboration income. Resource realignment and reduced R&D expenses suggest better operational efficiency and net margin improvement over the next year.
View narrative
US$8.33
FV
95.7% undervalued
intrinsic discount
-21.87%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
8
users have followed this narrative
4 days ago
author updated this narrative
Shield Therapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Global Aging Trends And Early Detection Will Unlock Markets
Key Takeaways An expanding addressable market and greater screening activity are driving strong prescription growth and recurring revenues for Shield's main product. Strategic partnerships, international expansion, and improved operational efficiency are positioned to enhance margins and drive sustained profit growth.
View narrative
UK£0.14
FV
66.5% undervalued
intrinsic discount
56.53%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
4 days ago
author updated this narrative
Value any company in seconds
Popular companies